Non-Hodgkin Lymphoma Diagnostics Market Size, Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2021 – 2027

Report ID: GMI4283

Summary Methodology

Non-Hodgkin Lymphoma Diagnostics Market size is projected to experience significant growth from 2019 to 2025.

Rising burden of Non-Hodgkin lymphoma will stimulate demand for Non-Hodgkin lymphoma diagnostics in the coming years. According to the Lymphoma Research Foundation, more than 72,000 Americans were diagnosed with Non-Hodgkin lymphoma in 2016. With increasing cases of NHL, the demand for preventive services will increase, thereby increasing the need for diagnostic kits. Above-mentioned factors will fuel industry growth over the forthcoming years.

Increasing awareness regarding causes and early diagnosis of cancer has resulted in development of better diagnostic tests, thereby boosting the market growth. Additionally, advances in detection techniques and introduction of new diagnostic kits will further pose lucrative business growth opportunities. For instance, liquid biopsy is a new technique for detection of cancers and is under clinical review for approval in detection of Non-Hodgkin lymphoma.

Rising awareness about blood cancer coupled with large number of unmet needs related to diagnosis and treatment of the disease will propel the growth of the Non-Hodgkin lymphoma diagnostics market. However, inadequate diagnostic results and high cost associated with the tests will impede the market growth up to some extent.

Biopsy testing will grow at a robust rate in the coming years due to high usage of excisional or incisional biopsy technique for diagnosis of Non-Hodgkin lymphoma. Biopsy is the only way to confirm whether the individual is suffering from NHL. Excisional and incisional biopsy technique is commonly preferred due to advantage of providing sufficient sample for diagnosis of NHL. Furthermore, introduction of novel biopsy techniques including liquid biopsy will assist the segmental growth in the coming years.  

Diffuse large B-cell lymphoma (DLBCL) segment will hold a significant revenue size over the estimated period. DLBCL is most common and rapidly growing type of Non-Hodgkin lymphoma. According to the World Health Organization, diffuse large B-cell lymphoma constitutes up to 40 percent cases of total Non-Hodgkin lymphoma cases globally. Immunohistochemistry is commonly used for diagnosis of DLBCL in clinical laboratories. With increasing prevalence and mortality associated with diffuse large B-cell lymphoma, the demand for accurate diagnostics for prevention will increase, thereby fueling industry growth.

Hospitals as end-use will dominate the market over the foreseeable future owing to high preference of patients for hospitals. Diagnosis of cancer in hospital is keystone for prevention, suppression, and treatment of Non-Hodgkin lymphoma. Availability of rapid and accurate diagnostic tests coupled with skilled professionals for the detection of disease will positively impact the industry growth.

U.S. Non-Hodgkin lymphoma diagnostics market will foresee momentous expansion due to rising incidence of Non-Hodgkin lymphoma in the region. According to the American Cancer Society, Non-Hodgkin lymphoma accounts for about 4% of all cancer cases in the U.S. Presence of well-established healthcare infrastructure and regulatory framework will further pose lucrative market growth opportunity. Additionally, high awareness regarding the disease amongst general population coupled with availability of large number of diagnostics centers will majorly impact industry growth during the forecast period.

India Non-Hodgkin lymphoma diagnostics market is anticipated to grow at a significant pace due to presence of large patient pool coupled with increasing healthcare expenditure. Adoption of urban lifestyle and economic progress in the country will further propel the occurrence of Non-Hodgkin lymphoma, thereby boosting market growth.   The unmet needs of the population and poor diagnostic facilities will further pose lucrative business growth opportunities in India for the industry players in the near future.


Some of the major companies involved in the global Non-Hodgkin lymphoma diagnostics market are Cardinal Health, Merit Medical Systems, BD, Thermo Fisher Scientific, Aspire Medical Innovation among others. Key players are adopting business expansion strategies and collaborations to expand their product portfolio. For instance, in November 2018, Merit Medical Systems and BD entered into an agreement. The deal helped Merit Medical Systems to acquire needle biopsy products of BD.


Non-Hodgkin Lymphoma Diagnostics Market by Test Type, 2014-2025 (USD Million)

  • Physical examination
  • Biopsy
    • Bone marrow aspiration and biopsy
    • Excisional or incisional biopsy
    • Needle biopsy
  • Cell and tissue study
    • Fluorescence in situ hybridization (FISH)
    • Polymerase chain reaction (PCR)
    • Immunophenotyping
  • Blood tests  
    • Complete blood count
    • Blood chemical test
  • Imaging tests 
    • Chest X-Ray
    • CT scan
    • MRI
    • Ultrasound
    • Bone scan
    • PET scan
  • Lumbar puncture

Non-Hodgkin Lymphoma Diagnostics Market by Lymphoma Type, 2014-2025 (USD Million)

  • Aggressive lymphomas
    • Diffuse large B-cell lymphoma
    • Anaplastic large-cell lymphoma
    • Burkitt lymphoma
    • Lymphoblastic lymphoma
    • Mantle cell lymphoma
    • Peripheral T-cell lymphoma
  • Indolent lymphomas
    • Follicular lymphoma
    • Cutaneous T-cell lymphoma
    • Lymphoplasmacytic lymphoma
    • Marginal zone B-cell lymphoma
    • MALT lymphoma
    • Small-cell lymphocytic lymphoma

Non-Hodgkin Lymphoma Diagnostics Market by End-Use, 2014-2025 (USD Million)

  • Hospitals
  • Diagnostic centers
  • Research laboratories

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
  • Latin America
    • Mexico
    • Brazil
    • Argentina
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • Kuwait
    • UAE

Company Profiles:

  • Cardinal Health
  • Merit Medical Systems
  • BD
  • Thermo Fisher Scientific
  • Aspire Medical Innovation
  • Medtronic
  • Depuy Synthes
  • Medplus Inc.
  • Merck KGaA
  • PerkinElmer, Inc.
  • Agilent Technologies, Inc
  • Abbott Laboratories

What Information does this report contain?

Historical data coverage: 2016 to 2020; Growth Projections: 2021 to 2027.
Expert analysis: industry, governing, innovation and technological trends; factors impacting development; drawbacks, SWOT.
6-7 year performance forecasts: major segments covering applications, top products and geographies.
Competitive landscape reporting: market leaders and important players, competencies and capacities of these companies in terms of production as well as sustainability and prospects.

Customize this Report

Pre Book Now

Need a Discount? Get in touch with us for special pricing

Request Discount

Our Market Research Reports Include:

  • Market snapshot
  • Market Segmentation
  • Value Chain Analysis
  • Growth Dynamics
  • Potential Market Opportunities
  • Regulatory Overview
  • Technology Evolution
  • Innovation & Sustainability

 Connect with our sales team

Chat with us
We use cookies to enhance user experience. (Privacy Policy) X